Data on sprytne.com is aggregated from official U.S. Government sources including the SEC EDGAR database, USAspending.gov, USPTO, and U.S. Census Bureau. In accordance with 17 U.S.C. § 105, works of the U.S. Government are not subject to copyright protection and reside in the Public Domain. sprytne.com provides value-added visualization and algorithmic analysis of these public records.
Not financial advice. sprytne.com is an automated market intelligence platform. We are not a registered investment advisor, broker, or dealer. Financial metrics, risk scores, and federal award data are for informational purposes only. Past performance (including government contract history) is not indicative of future market results. Verify all data via official SEC.gov filings.
This platform adheres to CCPA/GDPR standards regarding professional and public business data. Information displayed pertains to commercial entities and public officers in their professional capacity. For data verification or removal requests regarding non-public information, please visit our Contact page. Operated under Brand House Data Systems framework.
© 2026 sprytne.com — Institutional Data Intelligence — Federal Transparency Initiative
Top pharmaceutical preparations companies in Delaware, ranked by financial performance.
Delaware Sector Intelligence · Sprytne.com
In Delaware, the pharmaceutical preparations sector is led by AbbVie Inc. (ABBV) with $61.16B in annual revenue. The fastest-growing player is Viridian Therapeutics, Inc.\DE at +23359.9% YoY growth.
Based on the latest SEC EDGAR 10-K annual filings · Verified public data
Filter by State
| Rank | Company | Revenue | Details |
|---|---|---|---|
| #1 | AbbVie Inc.ABBV | $61.16B | YoY: +8.6% |
| #2 | PFIZER INCPFE | $50.91B | YoY: -44.5% |
| #3 | BRISTOL MYERS SQUIBB COBMY | $48.19B | YoY: -0.2% |
| #4 | Viatris IncVTRS | $14.25B | YoY: -3.0% |
| #5 | BIOMARIN PHARMACEUTICAL INCBMRN | $3.22B | YoY: +12.9% |
| #6 | UNITED THERAPEUTICS CorpUTHR | $3.18B | YoY: +10.6% |
| #7 | Sarepta Therapeutics, Inc.SRPT | $1.86B | YoY: +4.3% |
| #8 | PTC THERAPEUTICS, INC.PTCT | $1.73B | YoY: +114.5% |
| #9 | PHIBRO ANIMAL HEALTH CORPPAHC | $1.30B | YoY: +27.4% |
| #10 | Indivior Pharmaceuticals, Inc.INDV | $1.24B | YoY: +4.3% |
| #11 | ACADIA PHARMACEUTICALS INCACAD | $1.07B | YoY: +11.9% |
| #12 | Apellis Pharmaceuticals, Inc.APLS | $1.00B | YoY: +28.5% |
| #13 | MADRIGAL PHARMACEUTICALS, INC.MDGL | $958.4M | YoY: +432.1% |
| #14 | ANI PHARMACEUTICALS INCANIP | $883.4M | YoY: +43.8% |
| #15 | Harmony Biosciences Holdings, Inc.HRMY | $868.5M | YoY: +21.5% |
| #16 | ARROWHEAD PHARMACEUTICALS, INC.ARWR | $829.4M | YoY: +23258.2% |
| #17 | CORCEPT THERAPEUTICS INCCORT | $761.4M | YoY: +12.8% |
| #18 | Emergent BioSolutions Inc.EBS | $742.9M | YoY: -28.8% |
| #19 | Pacira BioSciences, Inc.PCRX | $726.4M | YoY: +3.6% |
| #20 | SUPERNUS PHARMACEUTICALS, INC.SUPN | $719.0M | YoY: +8.6% |
| #21 | Ultragenyx Pharmaceutical Inc.RARE | $673.0M | YoY: +20.2% |
| #22 | Axsome Therapeutics, Inc.AXSM | $638.5M | YoY: +65.5% |
| #23 | AMICUS THERAPEUTICS, INC.FOLD | $634.2M | YoY: +20.0% |
| #24 | TG THERAPEUTICS, INC.TGTX | $616.3M | YoY: +87.3% |
| #25 | CATALYST PHARMACEUTICALS, INC.CPRX | $589.0M | YoY: +19.8% |
| Rank | Company | YoY Growth | Details |
|---|---|---|---|
| #1 | Viridian Therapeutics, Inc.\DEVRDN | +23359.9% | Revenue: $70.8M |
| #2 | ARROWHEAD PHARMACEUTICALS, INC.ARWR | +23258.2% | Revenue: $829.4M |
| #3 | Septerna, Inc.SEPN | +4174.5% | Revenue: $46.0M |
| #4 | Spero Therapeutics, Inc.SPRO | +3292.5% | Revenue: $12.6M |
| #5 | IDEAYA Biosciences, Inc.IDYA | +3024.4% | Revenue: $218.7M |
| #6 | Liquidia CorpLQDA | +1031.2% | Revenue: $158.3M |
| #7 | Nuvation Bio Inc.NUVB | +699.0% | Revenue: $62.9M |
| #8 | Syndax Pharmaceuticals IncSNDX | +627.8% | Revenue: $172.4M |
| #9 | CorMedix Inc.CRMD | +617.0% | Revenue: $311.7M |
| #10 | Xilio Therapeutics, Inc.XLO | +589.9% | Revenue: $43.8M |
| #11 | MADRIGAL PHARMACEUTICALS, INC.MDGL | +432.1% | Revenue: $958.4M |
| #12 | Stoke Therapeutics, Inc.STOK | +404.5% | Revenue: $184.4M |
| #13 | ZEVRA THERAPEUTICS, INC.ZVRA | +350.9% | Revenue: $106.5M |
| #14 | NextCure, Inc.NXTC | +252.6% | Revenue: $22.4M |
| #15 | Phathom Pharmaceuticals, Inc.PHAT | +216.9% | Revenue: $175.1M |
| #16 | Cue Biopharma, Inc.CUE | +195.7% | Revenue: $27.5M |
| #17 | ANAPTYSBIO, INCANAB | +157.0% | Revenue: $234.6M |
| #18 | ASSEMBLY BIOSCIENCES, INC.ASMB | +153.5% | Revenue: $72.3M |
| #19 | Celularity IncCELU | +138.1% | Revenue: $54.2M |
| #20 | BridgeBio Pharma, Inc.BBIO | +126.3% | Revenue: $502.1M |
| #21 | Arcutis Biotherapeutics, Inc.ARQT | +123.4% | Revenue: $372.1M |
| #22 | HOOKIPA Pharma Inc.HOOK | +118.3% | Revenue: $43.9M |
| #23 | PTC THERAPEUTICS, INC.PTCT | +114.5% | Revenue: $1.73B |
| #24 | ARVINAS, INC.ARVN | +114.2% | Revenue: $46.7M |
| #25 | Eton Pharmaceuticals, Inc.ETON | +104.9% | Revenue: $80.0M |
| Rank | Company | Net Income | Details |
|---|---|---|---|
| #1 | PFIZER INCPFE | $7.77B | Margin: 15.3% |
| #2 | BRISTOL MYERS SQUIBB COBMY | $7.05B | Margin: 14.6% |
| #3 | AbbVie Inc.ABBV | $4.23B | Margin: 6.9% |
| #4 | UNITED THERAPEUTICS CorpUTHR | $1.33B | Margin: 41.9% |
| #5 | PTC THERAPEUTICS, INC.PTCT | $682.6M | Margin: 39.4% |
| #6 | TG THERAPEUTICS, INC.TGTX | $447.2M | Margin: 72.6% |
| #7 | ACADIA PHARMACEUTICALS INCACAD | $391.0M | Margin: 36.5% |
| #8 | RIGEL PHARMACEUTICALS INCRIGL | $367.0M | Margin: 124.7% |
| #9 | BIOMARIN PHARMACEUTICAL INCBMRN | $348.9M | Margin: 10.8% |
| #10 | CATALYST PHARMACEUTICALS, INC.CPRX | $214.3M | Margin: 36.4% |
| #11 | Indivior Pharmaceuticals, Inc.INDV | $210.0M | Margin: 16.9% |
| #12 | CorMedix Inc.CRMD | $163.1M | Margin: 52.3% |
| #13 | Harmony Biosciences Holdings, Inc.HRMY | $158.7M | Margin: 18.3% |
| #14 | Galera Therapeutics, Inc.GRTX | $149.0M | — |
| #15 | LIGAND PHARMACEUTICALS INCLGND | $124.5M | Margin: 46.4% |
| #16 | CORCEPT THERAPEUTICS INCCORT | $99.7M | Margin: 13.1% |
| #17 | ZEVRA THERAPEUTICS, INC.ZVRA | $83.2M | Margin: 78.2% |
| #18 | ANI PHARMACEUTICALS INCANIP | $78.3M | Margin: 8.9% |
| #19 | ABEONA THERAPEUTICS INC.ABEO | $71.2M | Margin: 1223.1% |
| #20 | ORAMED PHARMACEUTICALS INC.ORMP | $64.0M | Margin: 3202.5% |
| #21 | Emergent BioSolutions Inc.EBS | $52.6M | Margin: 7.1% |
| #22 | PHIBRO ANIMAL HEALTH CORPPAHC | $48.3M | Margin: 3.7% |
| #23 | AEON Biopharma, Inc.AEON | $42.0M | — |
| #24 | Organogenesis Holdings Inc.ORGO | $37.0M | Margin: 6.6% |
| #25 | PUMA BIOTECHNOLOGY, INC.PBYI | $31.1M | Margin: 13.6% |